ReviewClinical microbiology reviews2016
Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.
Review in Clinical microbiology reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Dose optimization of β-lactams antibiotics in pediatrics and adults: A systematic review.Frontiers in pharmacology · 2022Pooled it
- Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.Antimicrobial agents and chemotherapy · 2018Trial
- Article
- Silver Nanoparticles as Antibacterials: Synthesis, Characterization, and Molecular Simulations Against β-Lactamase-Producing Enterobacter and Salmonella spp.Molecular biotechnology · 2026Article
- Translating Pharmacokinetic-Pharmacodynamic Principles Into Improved Methodology for Clinical Trials That Compare Intermittent With Prolonged Infusion of Beta-Lactam Antibiotics.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Review
- Prolonged versus intermittent β-lactam infusion in sepsis: a systematic review and meta-analysis of randomized controlled trials.Annals of intensive care · 2024Review
- Extended Infusion of Beta-Lactams and Glycopeptides: A New Era in Pediatric Care? A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2024Review
- Impact of Key Components of Intensified Ceftaroline Dosing on Pharmacokinetic/Pharmacodynamic Target Attainment.Clinical pharmacokinetics · 2024Article
- Optimizing the Use of Beta-Lactam Antibiotics in Clinical Practice: A Test of Time.Open forum infectious diseases · 2023Article
- Effectiveness of Extended or Continuous vs. Bolus Infusion of Broad-Spectrum Beta-Lactam Antibiotics for Febrile Neutropenia: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2023Review
- Novel copper-containing ferrite nanoparticles exert lethality to MRSA by disrupting MRSA cell membrane permeability, depleting intracellular iron ions, and upregulating ROS levels.Frontiers in microbiology · 2023Article
- Optimizing Meropenem in Highly Resistant Klebsiella pneumoniae Environments: Population Pharmacokinetics and Dosing Simulations in Critically Ill Patients.Antimicrobial agents and chemotherapy · 2022Article
- Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in anAntimicrobial agents and chemotherapy · 2022Article
- A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
- Evaluation of Prolonged Versus Continuous Infusions of Piperacillin/Tazobactam During Shortages of Small Volume Parenteral Solutions.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2021Article
- Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study.Clinical pharmacokinetics · 2021Observational
- Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach.Antibiotics (Basel, Switzerland) · 2021Review
- Pseudomonas aeruginosa Ventilator-Associated Pneumonia Rabbit Model for Preclinical Drug Development.Antimicrobial agents and chemotherapy · 2021Article
- Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion.Clinical pharmacology in drug development · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Beta-lactam antibiotics serve as a cornerstone in the management of bacterial infections because of their wide spectrum of activity and low toxicity. Since resistance rates among bacteria are continuously on the rise and the pipeline for new antibiotics does not meet this trend, an optimization of current beta-lactam treatment is needed. This review provides an overview of optimization through use of prolonged- and continuous-infusion dosing strategies compared with more traditional intermittent infusions. Included is an overview of the scientific basis for using these nontraditional prolonged- and continuous-infusion-based regimens, with a focus on major areas in which the clinical laboratory can support the clinical use of these regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.